✓ Evidence-based health information Editorial Policy  |  Medical Review Board
Neurological Health

ALS: Understanding Amyotrophic Lateral Sclerosis

Written by Dr. Angela Brooks, MD, PhD, MD, PhD
Published
Updated
9 min read
Share: Facebook Tweet
Medically Reviewed This article has been reviewed for accuracy by the HealthTopics Medical Team. Our editorial process ensures content meets rigorous accuracy standards.
ALS: Understanding Amyotrophic Lateral Sclerosis
ALS: Understanding Amyotrophic Lateral Sclerosis – HealthTopics.com

Sarah noticed her right hand felt clumsy while buttoning her blouse one Tuesday morning—nothing dramatic, just that her fingers weren’t cooperating the way they always had. Within six weeks, she’d mentioned it to her primary care doctor, who initially blamed pinched nerves. By the time her neurologist confirmed amyotrophic lateral sclerosis three months later, the weakness had spread to her forearm and shoulder. She was 58 years old, and nobody in her family had ever had this disease.

ALS kills motor neurons, the cells your brain uses to command your muscles to move. It’s relentless, progressive, and there’s no cure—but understanding what’s actually happening inside your body transforms how you approach the diagnosis and what you can realistically expect from treatment.

Key Facts About ALS

  • Approximately 5,000 Americans receive an ALS diagnosis annually, with about 16,000 people living with the disease at any given time, according to the CDC
  • The average age of onset is 58 years old, though ALS can develop in people as young as 21
  • Men are 1.3 times more likely to develop ALS than women
  • About 90 percent of cases are sporadic (not inherited), while 10 percent run in families and follow clear genetic patterns
  • Median survival is 2 to 3 years from diagnosis, though 20 percent of patients live five years or longer

Understanding What ALS Actually Does

Think of motor neurons as the wiring inside your nervous system that carries electrical signals from your brain down through your spinal cord and out to your muscles. Those signals say “contract” and your muscles obey. In ALS, for reasons we still don’t fully understand, those motor neurons gradually fall apart. They die off. Once they’re gone, your brain can’t send signals to those muscles anymore, so they stop working.

The disease doesn’t affect sensation, cognition, or vision in most cases. You feel normal. You think clearly. But your body slowly stops listening to your commands. Your muscles weaken, then atrophy. Speech becomes slurred. Swallowing gets difficult. Eventually, the diaphragm—the muscle that drives breathing—weakens too.

Here’s the part that most articles gloss over: ALS kills motor neurons at different rates depending on which system it affects first. Someone with bulbar-onset ALS (affecting speech and swallowing muscles) often progresses faster than someone with limb-onset ALS (starting in the arms or legs). That trajectory matters enormously for planning.

Causes and Risk Factors

We don’t have a single cause. We have risk factors, and honestly, that’s frustrating for patients who want a clear answer about why this happened to them.

Genetics matter. If you carry mutations in genes like SOD1, C9orf72, or FUS, your risk is substantially elevated. A JAMA Neurology study showed that genetic testing now identifies pathogenic variants in approximately 15 percent of apparently sporadic ALS cases, meaning some people inherit ALS risk without knowing their family history.

Age is a factor—risk climbs after 55. Environmental exposures get discussed frequently: military service, head trauma, occupational chemical exposure, and heavy metal contact have all shown associations in epidemiological research. But these associations are modest, not deterministic.

Here’s what rarely gets discussed: strenuous physical activity and elite athletic careers show up consistently in epidemiological studies as a risk factor. Professional athletes and particularly competitive soccer and American football players have higher ALS rates than the general population. The mechanism remains unclear—is it repeated head trauma, intense metabolic demand on neurons, or something else entirely? We don’t know, but it’s worth knowing that intense physical exertion may carry risk rather than protection.

Signs and Symptoms You Actually Experience

Early symptoms are deceptively subtle. You might drop things more frequently. Your handwriting becomes messier. Climbing stairs feels harder than it used to. Some people notice their speech sounds different to others before they perceive it themselves—slightly slurred or nasal-sounding.

Bulbar symptoms—affecting the muscles of speech and swallowing—present differently. You might choke on liquids before solids, or feel like food is sticking in your throat. Your voice might tire quickly during conversation.

What actually surprises most people: fasciculations. These are visible twitches under the skin where muscles are dying off. You’ll see a ripple or twitch beneath the surface, usually in the forearm, calf, or tongue. They’re not painful, but they’re unsettling once you notice them.

Cramping is common and brutal. Unlike normal muscle cramps, ALS-related cramping doesn’t resolve with stretching. Your muscles tighten, and you just have to wait it out. Fatigue accumulates. Not sleepiness—exhaustion that doesn’t improve with rest.

Cognitive changes occur in about 50 percent of ALS patients, though frontotemporal dementia-like changes happen in a smaller subset. Most people stay mentally sharp.

Getting Diagnosed

Your neurologist won’t find ALS on a blood test or a single imaging study. The diagnosis is clinical, based on patterns of muscle weakness and electrical testing.

You’ll get an EMG—electromyography—where needles pick up the electrical activity of your muscles. In ALS, the pattern is distinctive: denervation potentials and fasciculations. You’ll also have an NCS, a nerve conduction study, which should be normal. That contrast is actually diagnostic—weak muscles with normal nerve conduction points toward the motor neuron itself, not the wiring connecting the nerve to the muscle.

MRI of your brain and spine rules out other things that look like ALS: tumors, compression, multiple sclerosis. Blood work screens for mimics.

Your neurologist applies the revised El Escorial criteria, looking for evidence of upper motor neuron disease (hyperreflexia, spasticity, Babinski sign) combined with lower motor neuron disease (weakness, atrophy, fasciculations) in multiple body regions. Definite ALS requires this pattern in two or more regions; probable ALS might have it in one region with supportive electromyography.

The process takes time. Initial evaluation might suggest “possible ALS” with follow-up testing in three months to see if the pattern becomes clearer. That waiting period is agonizing for patients, but it’s how the diagnosis is actually made.

Treatment Options

Riluzole was the first FDA-approved treatment for ALS, approved in 1995. It blocks glutamate, a neurotransmitter that appears to damage motor neurons. It extends median survival by about two to three months. That sounds small, but in a disease this aggressive, two months matters.

Edaravone, approved in 2017, is an antioxidant that showed modest benefit in slowing functional decline, particularly in early-stage disease. The NEJM trial showed a 33 percent slowing of decline over six months.

Sodium phenylbutyrate/taurursodiol (Relyvrio) combines two compounds that reduce neuroinflammation. It received accelerated approval in 2023 based on promising Phase 2 data, showing a 25 percent slowing of decline.

Physical therapy, occupational therapy, and speech-language pathology don’t stop the disease, but they preserve function longer. A speech pathologist teaches strategies before swallowing becomes dangerous. An occupational therapist modifies your home so you can stay independent as long as possible. Physical therapy prevents contractures and maintains range of motion.

Noninvasive ventilation—using a BiPAP mask at night—extends life significantly when breathing becomes affected. Invasive mechanical ventilation through a tracheostomy extends it further but fundamentally changes quality of life and requires 24-hour care.

Practical Daily Management

Use your dominant hand for essential tasks while you still can. Get adaptive equipment early: button hooks, long-handled shoehorns, reaching tools. These aren’t admissions of defeat; they’re practical engineering solutions.

Arrange your living space so daily necessities are accessible without walking far. Put your bedroom on the first floor if possible. A raised toilet seat and grab bars prevent falls.

Work with a nutritionist because swallowing difficulty sneaks up. You’ll switch from regular food to pureed foods, then to liquid nutrition. Plan that transition proactively rather than scrambling when you’re aspirating.

Communicate your wishes about ventilation and end-of-life care while you can write or speak clearly. These conversations are hard, but having them in advance prevents crisis decisions later.

Connect with an ALS Association support group. Hearing how others manage specific challenges—speech loss, feeding tubes, mobility aids—provides practical solutions and normalizes your experience.

Prevention

There’s no proven prevention strategy because we don’t understand causation well enough. The evidence on modifiable risk factors is inconsistent. Some studies suggest regular moderate exercise might have modest protective effects, but that research is preliminary and doesn’t apply once disease has started.

If you have a family history of ALS, genetic counseling and testing might identify whether you carry a mutation. That knowledge doesn’t change immediate management but could influence family planning and allows you to monitor yourself for early symptoms.

Frequently Asked Questions

Is ALS always fatal?

ALS is progressive and currently incurable, but it’s not uniformly fatal on a fixed timeline. About 20 percent of patients survive five years, and a small percentage live ten years or longer. Those with slower progression or younger age at onset tend to live longer. Invasive mechanical ventilation through a tracheostomy can extend life significantly, though it requires full-time care.

Can stress cause ALS?

Stress doesn’t cause ALS. ALS has genetic and environmental components, but emotional stress isn’t among them. That said, stress can worsen existing symptoms and accelerate fatigue, so managing stress through whatever means work for you is still valuable.

Will I lose mental function?

Most people with ALS maintain cognitive function throughout their illness. About 50 percent experience some cognitive changes, but full dementia is less common. Locked-in syndrome—where you’re conscious and aware but completely paralyzed—happens in severe ALS, so your mind remains sharp even as your body fails.

Can you work with ALS?

Many people work for some period after diagnosis, depending on disease progression and job type. Office work with voice recognition software remains feasible longer than physical labor. Accommodations through the ADA and modifications at work can extend your working years, but most people need to leave work within one to two years of diagnosis.

Should I try experimental treatments?

Clinical trials offer potential benefit and generate data that might help future patients. Discuss any trial your neurologist mentions—understand the protocol, time commitment, and potential risks. Some trials are more promising than others based on the mechanism being tested, so informed discussion with your neurologist is essential.

Sources & Medical References

HealthTopics.com articles are based on peer-reviewed medical research and guidance from the NIH, CDC, and WHO. See our editorial policy for full sourcing standards.

Dr. Angela Brooks, MD, PhD
Written by Dr. Angela Brooks, MD, PhD MD, PhD - Board-Certified Neurologist
Neurology & Neurological Disorders
Assistant Professor of Neurology, Mayo Clinic

Dr. Angela Brooks is a board-certified neurologist at Mayo Clinic specializing in movement disorders, epilepsy, and neurodegenerative diseases with 13 years of experience.

View Full Profile →